tldrdailynews.com logo
Tag

Melanoma

All articles tagged with #melanoma

business9 hours ago

Moderna Stock Rally Was Telegraphed by Early Trial Signals

Moderna’s shares jumped after Merck and Moderna announced that their Phase III melanoma trial of intismeran autogene with KEYTRUDA met its endpoints, a readout that was effectively foreshadowed by pre-announced signals: a fully enrolled study, Merck covering about half the trial cost, and prior commentary that implied a big move could come. The stock rose to around $145, within a 52-week range of roughly $22–$174, despite Moderna’s weaker 2025 results and restructuring. The piece highlights how identifying funded, binary events in a pipeline—well before a readout—can inform portfolio strategies, as demonstrated by Moderna’s surge.

via Trefis|
#business#melanoma#merck
Melanoma vaccine trial signals transformative path for cancer care
health2 days ago

Melanoma vaccine trial signals transformative path for cancer care

The Washington Post profiles Mark Orwig and other melanoma patients in a Moderna/M Merck trial testing an mRNA-based cancer vaccine. Early results suggest the vaccine could prevent cancer recurrence after surgery, a finding experts say could transform cancer care and accelerate FDA approval, despite participants experiencing side effects and a tough recovery.

via The Washington Post|
#cancer#clinical-trials#health
Personalized cancer vaccine from Moderna and Merck shows breakthrough in melanoma
health4 days ago

Personalized cancer vaccine from Moderna and Merck shows breakthrough in melanoma

Moderna and Merck reported a personalized mRNA cancer vaccine used with Keytruda that reduced melanoma recurrence and spread in a trial of more than 1,000 patients, with five-year data from earlier results showing about a 50% drop in recurrence and a 59% drop in spread versus Keytruda alone; if approved, thousands of melanoma patients could benefit in the first years, and trials in other cancers (lung, bladder, kidney, pancreatic, stomach) are ongoing with results expected in the coming years.

via CNN|
#cancer-vaccine#health#keytruda
Moderna’s Cancer Vaccine Breakthrough Triggers Massive Rally, Then Profit-Taking
investing5 days ago

Moderna’s Cancer Vaccine Breakthrough Triggers Massive Rally, Then Profit-Taking

Moderna’s personalized cancer vaccine mRNA-4157 (intismeran autogene) paired with Merck’s Keytruda hit key Phase 3 melanoma endpoints, delivering a 49% reduction in recurrence or death versus Keytruda alone and sparking a 177% one‑day stock surge before shares retraced about 20% as investors took profits; Moderna’s pipeline spans nine Phase 2/3 studies across melanoma, NSCLC, bladder and kidney cancers, despite a $950 million settlement and a norovirus program setback, while Merck’s KEYTRUDA franchise remains a critical driver for oncology growth.

via 24/7 Wall St.|
#cancer-vaccine#investing#melanoma
Personalized mRNA Melanoma Vaccine Extends Recurrence-Free Survival in Phase 3
health5 days ago

Personalized mRNA Melanoma Vaccine Extends Recurrence-Free Survival in Phase 3

Moderna and Merck reported Phase 3 results for intismeran autogene (a personalized mRNA cancer vaccine) combined with Keytruda in high-risk melanoma patients after surgery, showing longer recurrence-free and metastasis-free survival versus Keytruda alone; safety was consistent with prior data. If confirmed, the vaccine could reshape cancer prevention and treatment and bolster mRNA vaccine credibility, but overall survival results and external validation are still pending.

via Gizmodo|
#cancer-immunotherapy#clinical-trials#fda-approval
Moderna Surges on Cancer Vaccine Breakthrough, Emerges as Market Darling
markets6 days ago

Moderna Surges on Cancer Vaccine Breakthrough, Emerges as Market Darling

Moderna’s personalized mRNA cancer vaccine Intismeran Autogene, developed with Merck, showed Phase 3 melanoma trial success when paired with Keytruda, triggering a roughly 176% stock rally and making Moderna the S&P 500’s second-best performer this year as analysts boost bets on its cancer pipeline, though the magnitude of benefit and potential launches remain under review.

via Yahoo Finance|
#intismeran-autogene#markets#melanoma
Moderna and Merck's mRNA cancer vaccine shows promising melanoma results, lifting shares
business6 days ago

Moderna and Merck's mRNA cancer vaccine shows promising melanoma results, lifting shares

Moderna and Merck reported that their experimental mRNA cancer vaccine, intismeran, when combined with Merck’s Keytruda, produced a clinically meaningful improvement in high-risk melanoma across more than 1,100 patients, with safety consistent with prior studies; the trial could pave the way for a commercial launch next year and signals potential for an expanded mRNA cancer platform, triggering a sharp rally in Moderna’s stock and a solid gain for Merck.

via axios.com|
#business#intismeran#keytruda
Personalized mRNA vaccine plus Keytruda shows promising Phase 3 melanoma results
health6 days ago

Personalized mRNA vaccine plus Keytruda shows promising Phase 3 melanoma results

Moderna and Merck report that adding the patient-specific mRNA cancer vaccine intismeran (mRNA-4157) to Merck’s Keytruda significantly extended recurrence-free and distant metastasis-free survival versus Keytruda alone in a Phase 3 trial of 1,137 melanoma patients. Interim results suggest meaningful benefit, with mature overall-survival data still pending; five-year Phase 2 data had previously shown substantial risk reductions. Full details will be presented at an upcoming conference.

via Ars Technica|
#health#immunotherapy#melanoma
Moderna-Merck mRNA vaccine shows promise in delaying melanoma recurrence
health7 days ago

Moderna-Merck mRNA vaccine shows promise in delaying melanoma recurrence

Moderna and Merck report interim Phase 3 results suggesting their personalized mRNA cancer vaccine Intismeran, used with Keytruda after melanoma surgery, may delay cancer recurrence in high-risk patients; data have not yet been peer‑reviewed and will be presented at a medical meeting and shared with regulators as the trial continues to assess overall survival.

via NBC News|
#health#immunotherapy#intismeran
Merck-Moderna melanoma vaccine combo shows phase 3 win for delaying recurrence
health7 days ago

Merck-Moderna melanoma vaccine combo shows phase 3 win for delaying recurrence

Merck and Moderna reported positive phase 3 results for a personalized mRNA cancer vaccine used with Keytruda in melanoma patients who had surgery, significantly extending disease-free survival and reducing the risk of distant metastasis versus Keytruda alone; safety was comparable to vaccines, and the teams will pursue regulatory submissions while continuing to assess overall survival.

via cnbc.com|
#health#keytruda#melanoma
Personalized mRNA cancer vaccine clears Phase 3 hurdle in melanoma
health7 days ago

Personalized mRNA cancer vaccine clears Phase 3 hurdle in melanoma

A patient-specific mRNA vaccine (intismeran autogene) combined with Keytruda met the Phase 3 primary endpoint in a 1,137-patient trial of resected melanoma, improving recurrence-free survival and potentially paving the way for the first FDA-approved mRNA-based cancer therapy; full data are to be presented later, with safety profile consistent with Keytruda.

via washingtonpost.com|
#cancer-immunotherapy#health#keytruda
Iowa’s Melanoma Rate Surges to Fourth in the U.S. Driven by Population Demographics
health15 days ago

Iowa’s Melanoma Rate Surges to Fourth in the U.S. Driven by Population Demographics

The 2026 Cancer in Iowa report estimates about 1,500 Iowans will be diagnosed with melanoma this year, placing Iowa fourth in the nation for melanoma incidence (33.7 per 100,000). Since 1992, rates have risen 169%, a trend attributed largely to Iowa’s predominantly white population (87.7%). Dermatologists say there is no credible link between sunscreen and cancer, and prevention focuses on sun protection (sunscreen, protective clothing, hats) and avoiding tanning beds, with many cases treated in office settings under the state’s cancer registry network.

via KCCI|
#health#iowa#iowa-cancer-registry